Grifols (NASDAQ:GRFS) Raised to Strong-Buy at Wall Street Zen

Grifols (NASDAQ:GRFS - Get Free Report) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research note issued to investors on Monday.

Separately, JPMorgan Chase & Co. raised their price objective on shares of Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a research note on Tuesday, June 17th.

Grifols Stock Performance

Shares of NASDAQ:GRFS traded up $0.25 during trading on Monday, reaching $9.64. The stock had a trading volume of 980,187 shares, compared to its average volume of 1,089,941. Grifols has a 52 week low of $6.19 and a 52 week high of $9.96. The firm has a market capitalization of $6.63 billion, a price-to-earnings ratio of 8.22, a P/E/G ratio of 0.32 and a beta of 0.55. The company has a quick ratio of 0.97, a current ratio of 2.60 and a debt-to-equity ratio of 1.13. The stock has a fifty day simple moving average of $8.37 and a two-hundred day simple moving average of $7.73.

Institutional Investors Weigh In On Grifols

Hedge funds and other institutional investors have recently modified their holdings of the stock. Versant Capital Management Inc acquired a new stake in shares of Grifols in the first quarter worth $28,000. Tower Research Capital LLC TRC grew its stake in shares of Grifols by 354.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock worth $60,000 after acquiring an additional 6,335 shares during the last quarter. First Trust Advisors LP acquired a new stake in Grifols during the fourth quarter worth $75,000. Envestnet Portfolio Solutions Inc. acquired a new stake in Grifols during the fourth quarter worth $77,000. Finally, Ballentine Partners LLC acquired a new stake in Grifols during the first quarter worth $77,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.